We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test 24 Hours After Start of Chemotherapy Predicts Survival

By LabMedica International staff writers
Posted on 11 Jan 2023

Acute myeloid leukemia is an aggressive blood cancer with poor survival. More...

Despite high rates of initial chemotherapy response, patients often relapse due to the selection and development of chemotherapy-resistant leukemic cells. The response to therapy is currently measured after weeks to months of treatment, thereby losing important time. Now, researchers have found a new method that within hours can predict if certain cancer patients will survive or not after chemotherapy.

Researchers at the University of Bergen (Bergen, Norway) have discovered that an immediate response to chemotherapy can be measured by investigating the functional properties of the leukemic cells. In their study, the researchers employed mass cytometry to investigate intracellular signaling networks in peripheral blood samples from 32 newly-diagnosed acute myeloid leukemia patients during the first 24 hours of standardized induction chemotherapy. By correlating initial intracellular signaling response to five-year overall survival, the researchers demonstrated that early response evaluation by mass cytometry at 24 hours can identify patients with suboptimal treatment response to standard induction therapy.

"When treating patients with leukemia, it is challenging to quickly follow if the patient is responding to therapy or not," said Benedicte Sjo Tislevoll, researcher at the University of Bergen and leader of the new study. "Our results show that the protein ERK1/2 increases within the first 24 hours of chemotherapy in patients who have a poor response to therapy. We believe that this protein is responsible for the cancer cells' resistance to chemotherapy and can be used to distinguish responders from non-responders."

"We think that this is an important key in our understanding of cancer, and our aim is to use this information to change treatment early for patients who are not responding to therapy," Tislevoll concluded.

Related Links:
University of Bergen 


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.